These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
95 related articles for article (PubMed ID: 29391202)
1. Phylogenetic analysis, structure modeling and docking study of HCV NS3 protease for the identification of potent inhibitors. Zia A; Abbasi SW; Ahmad S; Zia M; Raza A Infect Genet Evol; 2018 Apr; 59():51-62. PubMed ID: 29391202 [TBL] [Abstract][Full Text] [Related]
2. Identification of potential inhibitors for HCV NS3 genotype 4a by combining protein-ligand interaction fingerprint, 3D pharmacophore, docking, and dynamic simulation. El-Hasab MAE; El-Bastawissy EE; El-Moselhy TF J Biomol Struct Dyn; 2018 May; 36(7):1713-1727. PubMed ID: 28531373 [TBL] [Abstract][Full Text] [Related]
3. Docking studies of Pakistani HCV NS3 helicase: a possible antiviral drug target. Fatima K; Mathew S; Suhail M; Ali A; Damanhouri G; Azhar E; Qadri I PLoS One; 2014; 9(9):e106339. PubMed ID: 25188400 [TBL] [Abstract][Full Text] [Related]
4. A comparative study of the efficiency of HCV NS3/4A protease drugs against different HCV genotypes using in silico approaches. Ezat AA; Elshemey WM Life Sci; 2019 Jan; 217():176-184. PubMed ID: 30528183 [TBL] [Abstract][Full Text] [Related]
5. Development of robust in vitro serine protease assay based on recombinant Pakistani HCV NS3-4A protease. Fatima K; Tahir M; Qadri I Virus Res; 2011 Sep; 160(1-2):230-7. PubMed ID: 21756947 [TBL] [Abstract][Full Text] [Related]
6. Rational Drug Discovery of HCV Helicase Inhibitor: Improved Docking Accuracy with Multiple Seeding in AutoDock Vina and In Situ Minimization. Lim SK; Othman R; Yusof R; Heh CH Curr Comput Aided Drug Des; 2017; 13(2):160-169. PubMed ID: 27903217 [TBL] [Abstract][Full Text] [Related]
7. Molecular models of NS3 protease variants of the Hepatitis C virus. da Silveira NJ; Arcuri HA; Bonalumi CE; de Souza FP; Mello IM; Rahal P; Pinho JR; de Azevedo WF BMC Struct Biol; 2005 Jan; 5():1. PubMed ID: 15663787 [TBL] [Abstract][Full Text] [Related]
8. In silico identification, design and synthesis of novel piperazine-based antiviral agents targeting the hepatitis C virus helicase. Bassetto M; Leyssen P; Neyts J; Yerukhimovich MM; Frick DN; Courtney-Smith M; Brancale A Eur J Med Chem; 2017 Jan; 125():1115-1131. PubMed ID: 27810598 [TBL] [Abstract][Full Text] [Related]
9. Analysis of the Enzymatic Activity of an NS3 Helicase Genotype 3a Variant Sequence Obtained from a Relapse Patient. Provazzi PJ; Mukherjee S; Hanson AM; Nogueira ML; Carneiro BM; Frick DN; Rahal P PLoS One; 2015; 10(12):e0144638. PubMed ID: 26658750 [TBL] [Abstract][Full Text] [Related]
10. Designing and molecular docking of cyclic peptides against HCV NS3 protease. Masoud MS; Bukhari SA; Qasim M; Naqvi SAR; Ashfaq UA Pak J Pharm Sci; 2017 Sep; 30(5(Supplementary)):1965-1969. PubMed ID: 29105629 [TBL] [Abstract][Full Text] [Related]
11. Understanding the structural and energetic basis of inhibitor and substrate bound to the full-length NS3/4A: insights from molecular dynamics simulation, binding free energy calculation and network analysis. Xue W; Wang M; Jin X; Liu H; Yao X Mol Biosyst; 2012 Oct; 8(10):2753-65. PubMed ID: 22833015 [TBL] [Abstract][Full Text] [Related]
12. In silico identification and evaluation of leads for the simultaneous inhibition of protease and helicase activities of HCV NS3/4A protease using complex based pharmacophore mapping and virtual screening. Wadood A; Riaz M; Uddin R; Ul-Haq Z PLoS One; 2014; 9(2):e89109. PubMed ID: 24551230 [TBL] [Abstract][Full Text] [Related]